Irritable Bowel Syndrome | Unmet Need | Constipation Predominant | US/EU | 2018
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label from indications such as CIC or OIC. Therapies are currently approved primarily based on the patient response rate to various end points, but physicians indicate that drugs capable of delivering superior relief and improving QOL metrics are a key unmet need.
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for IBS-C?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for IBS-C?
- What are the prevailing areas of unmet need and opportunity in IBS-C?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European gastroenterologists for a hypothetical new IBS-C drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, and Germany.
Primary research: Survey of 60 U.S. and 32 European gastroenterologists fielded in January 2018.
Key companies: Allergan/Ironwood, Mallinckrodt/Takeda, and Synergy.
Key drugs: Linzess/Constella, Amitiza, and Trulance.
